PharmTech Drug Digest 11.20
News|Articles|February 3, 2016

LabConnect Builds New Biorepository Facility

LabConnect built a biorepository facility in Tennessee.

LabConnect, a Seattle-based provider of laboratory services to biopharmaceutical, medical device, and contract research organizations, has built a new biorepository facility to expand services and better meet the evolving needs of the industry.

According to a Feb. 3, 2016 press announcement from the company, LabConnect’s new, 5000-square-foot biorepository in Johnson City, TN, includes space for ambient, refrigerated, cold (-20 °C), and ultra-low temperature (-70 to -80 °C) storage as well as liquid nitrogen vapor phase storage (-190 °C).

“Proper sample management is essential to both today’s and tomorrow’s clinical trials,” said Eric Hayashi, LabConnect president and CEO, in the press release. “Researchers depend on the integrity and availability of their stored biospecimens to retest them to verify trends or unexpected results, or for later retrieval to support specific biomarker research.”

The facility includes storage capacity for more than 8 million samples, fully validated and mapped backup freezers and generators, redundant HVAC systems, whole building and biorepository security systems, and a temperature monitoring system for all freezers and refrigerators with a 21 CFR Part 11 compliant audit trail. LabConnect also tracks sample locations and consolidates data within a centralized database. 

Source: LabConnect


Related to this article

white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Green Chemistry Supply and Demand in Sustainable Pharma
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.